- Home
- JANX vs DEA Comparison
JANX vs DEA Comparison
Compare JANX & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | DEA |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 975.7M | 1.1B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JANX | DEA |
|---|---|---|
| Price | $18.05 | $24.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | ★ $47.00 | $23.49 |
| AVG Volume (30 Days) | ★ 670.8K | 334.0K |
| Earning Date | 05-08-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 7.77% |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ 0.08 |
| Revenue | $10,000,000.00 | ★ $336,099,000.00 |
| Revenue This Year | N/A | $5.41 |
| Revenue Next Year | N/A | $3.33 |
| P/E Ratio | ★ N/A | $307.25 |
| Revenue Growth | N/A | ★ 11.27 |
| 52 Week Low | $12.12 | $20.56 |
| 52 Week High | $35.34 | $25.96 |
Technical Indicators
Market Signals| Indicator | JANX | DEA |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 49.76 |
| Support Level | $13.13 | $24.30 |
| Resistance Level | $35.34 | $25.07 |
| Average True Range (ATR) | 0.64 | 0.44 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 82.07 | 63.08 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.